Early Graft, Limb and Mortality Outcomes from the Omniflow II Bio-Synthetic Graft.

Author(s): Evans W; Department of Vascular Surgery, East Lancashire Hospitals NHS Trust
Buchanan J; Department of Vascular Surgery, East Lancashire Hospitals NHS Trust
Goel R; Department of Vascular Surgery, East Lancashire Hospitals NHS Trust
Hardy S; Department of Vascular Surgery, East Lancashire Hospitals NHS Trust
​et al. 
Source: Annals of vascular surgery, 2022 Jan; Vol. 78, pp. 321-327
Abstract: Omniflow II biosynthetic grafts are a commonly used alternative to autologous grafts in vascular bypass procedures. They are chosen for their purported resilience to infection, often in instances of existing graft failure or infection. We examined the short term, 1-3 year outcomes of Omniflow grafts in terms of patency, limb survival and mortality in a sample of 24 individuals.; Methods: This is a single centred retrospective study of Omniflow II grafts implanted between September 23, 2015 and April 05, 2018 in our department. We found that rates of primary patency and limb salvage for this graft type were markedly lower than in comparable studies. Further work in the form of a RCT is indicated. 

• Request full text access from the library